StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.17−0.71 (-2.64%)

Close on Nov 18, 2026Market cap $3.34BP/E –Yield –

Viking Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Viking Therapeutics

Viking Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Viking Therapeutics figures

See a number that looks wrong?